[go: up one dir, main page]

JOP20130213B1 - معارضات لمستقبلht3-5 - Google Patents

معارضات لمستقبلht3-5

Info

Publication number
JOP20130213B1
JOP20130213B1 JOP/2013/0213A JOP20130213A JOP20130213B1 JO P20130213 B1 JOP20130213 B1 JO P20130213B1 JO P20130213 A JOP20130213 A JO P20130213A JO P20130213 B1 JOP20130213 B1 JO P20130213B1
Authority
JO
Jordan
Prior art keywords
compounds
oppositions
future
disorders
receptor
Prior art date
Application number
JOP/2013/0213A
Other languages
English (en)
Inventor
Maria Hopkins
Holly Reichard
Huikai Sun
Shota Kikuchi
Holger Monenschein
Todd Macklin
Steve Hitchcock
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48877569&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20130213(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Application granted granted Critical
Publication of JOP20130213B1 publication Critical patent/JOP20130213B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/38—Acyl halides
    • C07C53/40—Acetyl halides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/12—Oxygen atoms acylated by aromatic or heteroaromatic carboxylic acids, e.g. cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

يوفر الاختراع الحالي معارضات لمستقبل 5-HT3 (5-HT3 receptor antagonists) من الصيغة (I): حيث تكون مفيدة لمعالجة أمراض يمكن معالجتها بتثبيط مستقبل 5-HT3 مثل القيء, الألم, إدمان عقار, التحلل العصبي واضطرابات نفسية, واضطرابات معدية معوية GI. تتوافر أيضا تركيبات دوائية تحتوي على هذه المركبات وعمليات لتحضيرها.
JOP/2013/0213A 2012-07-17 2013-07-11 معارضات لمستقبلht3-5 JOP20130213B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261672709P 2012-07-17 2012-07-17
US201261708521P 2012-10-01 2012-10-01

Publications (1)

Publication Number Publication Date
JOP20130213B1 true JOP20130213B1 (ar) 2021-08-17

Family

ID=48877569

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0213A JOP20130213B1 (ar) 2012-07-17 2013-07-11 معارضات لمستقبلht3-5

Country Status (43)

Country Link
US (8) US9012447B2 (ar)
EP (3) EP2875012B1 (ar)
JP (5) JP5816400B2 (ar)
KR (1) KR102148969B1 (ar)
CN (2) CN104768943B (ar)
AP (1) AP2015008240A0 (ar)
AR (1) AR091781A1 (ar)
AU (1) AU2013290375B2 (ar)
BR (1) BR112015001028B1 (ar)
CA (1) CA2879115C (ar)
CL (1) CL2015000121A1 (ar)
CO (1) CO7280468A2 (ar)
CR (1) CR20150057A (ar)
CY (1) CY1120881T1 (ar)
DK (2) DK3312169T3 (ar)
DO (1) DOP2015000009A (ar)
EA (1) EA025986B1 (ar)
EC (1) ECSP15004780A (ar)
ES (2) ES2659758T3 (ar)
GE (1) GEP201606526B (ar)
HR (1) HRP20180523T1 (ar)
HU (2) HUE056710T2 (ar)
IL (1) IL236702B (ar)
IN (1) IN2015DN00957A (ar)
JO (1) JOP20130213B1 (ar)
LT (1) LT2875011T (ar)
ME (1) ME03005B (ar)
MX (1) MX359733B (ar)
MY (1) MY182432A (ar)
NZ (1) NZ704814A (ar)
PE (1) PE20150671A1 (ar)
PH (1) PH12015500085A1 (ar)
PL (2) PL3312169T3 (ar)
PT (2) PT2875011T (ar)
RS (1) RS57096B1 (ar)
SG (1) SG11201500302UA (ar)
SI (1) SI2875011T1 (ar)
SM (1) SMT201800177T1 (ar)
TN (1) TN2015000018A1 (ar)
TW (1) TWI602821B (ar)
UY (1) UY34912A (ar)
WO (2) WO2014014962A1 (ar)
ZA (1) ZA201500781B (ar)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20130213B1 (ar) * 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
SG10201900536TA (en) * 2014-03-06 2019-02-27 Shanghai Haiyan Pharmaceutical Tech Co Ltd Piperidine derivatives as orexin receptor antagonist
DK3201203T3 (da) * 2014-09-29 2021-08-23 Takeda Pharmaceuticals Co Krystallinsk form af 1-(1-methyl-1h-pyrazol-4-yl)-n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1h-indol-3-carboxamid
EP3233087B1 (en) 2014-12-16 2019-10-02 Axovant Sciences GmbH Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
US10370370B2 (en) 2015-06-10 2019-08-06 Axovant Sciences Gmbh Aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors
WO2017027600A1 (en) 2015-08-12 2017-02-16 Forum Pharmaceuticals, Inc. GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF α7-NICOTINIC ACETYLCHOLINE RECEPTORS
EP3600291A4 (en) * 2017-03-27 2020-12-23 Chase Therapeutics Corporation COMPOSITIONS AND METHODS OF TREATMENT OF SYNUCLEINOPATHIES
EA201992532A1 (ru) * 2017-04-24 2020-04-03 Чейс Терапьютикс Корпорейшн Композиции и способ для лечения депрессии
EA202090180A1 (ru) 2017-06-30 2020-05-26 Чейс Терапьютикс Корпорейшн Композиции nk1-антагониста и способы лечения депрессии
WO2019180176A1 (en) 2018-03-21 2019-09-26 Spherium Biomed, S.L. Composition for the treatment of schizophrenia and/or psychosis
WO2020068913A1 (en) * 2018-09-25 2020-04-02 Chase Therapeutics Corporation Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases
WO2021026380A1 (en) * 2019-08-07 2021-02-11 Alkermes, Inc. Phenyltriazole compounds for the treatment of pain
WO2021026378A1 (en) * 2019-08-07 2021-02-11 Alkermes, Inc. Indole compounds for the treatment of pain
CN119156388A (zh) * 2022-04-15 2024-12-17 海南先声再明医药股份有限公司 膜缔合酪氨酸和苏氨酸激酶抑制剂
WO2025077825A1 (en) * 2023-10-13 2025-04-17 Fauna Bio Incorporated Methods and compositions for treating cardio-pulmonary disorders

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4273963A (en) 1979-05-25 1981-06-16 Bell Telephone Laboratories, Incorporated Automatic equalization for digital transmission systems
DE3033568A1 (de) 1980-09-05 1982-05-06 Marker, Hannes, 8100 Garmisch-Partenkirchen Fersenhalter einer sicherheits-skibindung
JPS5816400A (ja) 1981-07-21 1983-01-31 松下電器産業株式会社 交通信号制御機
FI74707C (fi) 1982-06-29 1988-03-10 Sandoz Ag Foerfarande foer framstaellning av terapeutiskt anvaendbara alkylenoeverbryggade piperidylestrar eller -amider av bicykliska karboxylsyror.
JPS5936675A (ja) 1982-07-13 1984-02-28 サンド・アクチエンゲゼルシヤフト 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド
GB8525913D0 (en) 1985-10-21 1985-11-27 Beecham Group Plc Compounds
GB8510752D0 (en) * 1985-04-27 1985-06-05 Beecham Group Plc Compounds
EP0200444B1 (en) * 1985-04-27 1992-11-11 Beecham Group Plc Azabicyclononyl-indazole-carboxamide having 5-ht antagonist activity
JPS6275675A (ja) 1985-09-30 1987-04-07 Toshiba Corp 画像形成装置
US4910193A (en) 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
DE3722069A1 (de) 1986-08-21 1988-02-25 Toyoda Gosei Kk Signalhornschaltvorrichtung fuer ein steuerrad
EP0279114B2 (en) 1986-11-21 1995-08-23 Glaxo Group Limited Medicaments for the treatment or prevention of the withdrawal syndrome
IT1226389B (it) 1988-07-12 1991-01-15 Angeli Inst Spa Nuovi derivati ammidinici e guanidinici
NZ230068A (en) 1988-07-29 1991-07-26 Dainippon Pharmaceutical Co Indazole-3-carboxylic acid esters and amides of diaza compounds having 6,7, or 8 ring members: preparatory processes and pharmaceutical compositions
GB8829079D0 (en) * 1988-12-13 1989-01-25 Beecham Group Plc Novel compounds
JPH0421681A (ja) * 1990-05-14 1992-01-24 Fujisawa Pharmaceut Co Ltd ピロロピリジン誘導体
JP3251954B2 (ja) * 1990-07-31 2002-01-28 日清ファルマ株式会社 アザビシクロ誘導体
US5187166A (en) * 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
HU211081B (en) 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5149962A (en) 1991-06-03 1992-09-22 Simmonds Precision Products, Inc. Proximity detector using faraday effect and bidirectional transmission
JP3407916B2 (ja) * 1992-01-31 2003-05-19 日清ファルマ株式会社 ジアザビシクロ誘導体
US5344831A (en) 1992-01-31 1994-09-06 Nisshin Flour Milling Co., Ltd. Diazabicyclo derivatives
GB9216154D0 (en) 1992-07-30 1992-09-09 Glaxo Group Ltd Chemical compounds
GB9406857D0 (en) 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
CA2160420A1 (en) * 1994-10-20 1996-04-21 Haruhiko Kikuchi 5-ht4 receptor agonists
JP3904254B2 (ja) * 1994-10-20 2007-04-11 株式会社日清製粉グループ本社 ５−ｈｔ４受容体作動薬
WO1996012722A1 (fr) * 1994-10-20 1996-05-02 Nisshin Flour Milling Co., Ltd. Agoniste des recepteurs 5-ht¿4?
WO2000044743A1 (fr) * 1999-01-28 2000-08-03 Nippon Shinyaku Co., Ltd. Derives d'amides et compositions de medicaments
WO2001043746A1 (fr) * 1999-12-14 2001-06-21 Nippon Shinyaku Co., Ltd. Composition medicinale
CA2460680A1 (en) 2001-09-19 2003-05-01 Pharmacia Corporation Substituted indazole compounds for the treatment of inflammation
US20040038958A1 (en) 2002-07-11 2004-02-26 Chris Rundfeldt Topical treatment of skin diseases
HRP20050266A2 (en) 2002-09-25 2005-10-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and uses thereof
JP2006516976A (ja) 2003-01-13 2006-07-13 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 機能性腸障害を処置する方法
EP1615698B1 (en) 2003-04-11 2010-09-29 High Point Pharmaceuticals, LLC New amide derivatives and pharmaceutical use thereof
EP2336128A1 (en) * 2004-03-25 2011-06-22 Memory Pharmaceuticals Corporation Benzoisothiazoles and preparation and uses thereof
CN101001856A (zh) * 2004-03-25 2007-07-18 记忆药物公司 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑及其制备和用途
CA2594773A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflammation
EP1940833A1 (en) 2005-09-23 2008-07-09 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
EP1984334B1 (en) 2006-02-15 2014-04-09 Allergan, Inc. Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (s1p) receptor antagonist biological activity
CN101460458A (zh) 2006-02-15 2009-06-17 阿勒根公司 具有1－磷酸－鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚－3－羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物
PL2041088T3 (pl) 2006-06-28 2014-07-31 Amgen Inc Inhibitory transportera-1 glicyny
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
JP2010518025A (ja) 2007-02-05 2010-05-27 アミラ ファーマシューティカルス，インコーポレーテッド ５−リポキシゲナーゼ活性化タンパク質（ｆｌａｐ）インヒビターとしての逆インドール
AU2008216382A1 (en) 2007-02-12 2008-08-21 Array Biopharma, Inc. Novel inhibitors hepatitis C virus replication
CN101778850A (zh) * 2007-08-10 2010-07-14 H.隆德贝克有限公司 杂芳基酰胺类似物
FR2921342B1 (fr) * 2007-09-20 2010-03-12 Airbus France Carenage aerodynamique arriere inferieur pour dispositif d'accrochage d'un moteur d'aeronef
WO2009108551A2 (en) * 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues
WO2009155054A2 (en) 2008-05-29 2009-12-23 Albany Molecular Research, Inc. 5-ht3 receptor modulators, methods of making, and use thereof
US20100113405A1 (en) 2008-11-06 2010-05-06 Auspex Pharmaceuticals, Inc. Methylindazole modulators of 5-ht3 receptors
TWI429628B (zh) 2010-03-29 2014-03-11 Univ Taipei Medical 吲哚基或吲哚啉基羥肟酸化合物
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
JOP20130213B1 (ar) * 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
JP6299097B2 (ja) 2013-07-22 2018-03-28 株式会社リコー 情報処理システム、情報処理方法、プログラム、及び記録媒体

Also Published As

Publication number Publication date
WO2014014951A1 (en) 2014-01-23
PT2875011T (pt) 2018-03-21
ECSP15004780A (es) 2018-07-31
CA2879115A1 (en) 2014-01-23
CA2879115C (en) 2021-03-02
LT2875011T (lt) 2018-05-10
PH12015500085B1 (en) 2015-04-13
NZ704814A (en) 2017-08-25
EP3312169B1 (en) 2021-09-15
US20170260201A1 (en) 2017-09-14
JP5816400B2 (ja) 2015-11-18
HUE038757T2 (hu) 2018-11-28
JP2018065827A (ja) 2018-04-26
CO7280468A2 (es) 2015-05-29
AR091781A1 (es) 2015-02-25
EP2875012B1 (en) 2019-09-04
SMT201800177T1 (it) 2018-05-02
IN2015DN00957A (ar) 2015-06-12
RS57096B1 (sr) 2018-06-29
AU2013290375A1 (en) 2015-02-19
US9346829B2 (en) 2016-05-24
HUE056710T2 (hu) 2022-03-28
US20180327421A1 (en) 2018-11-15
JP6479145B2 (ja) 2019-03-06
TN2015000018A1 (en) 2016-06-29
US20140024644A1 (en) 2014-01-23
EP3312169A1 (en) 2018-04-25
KR102148969B1 (ko) 2020-08-27
US9303045B2 (en) 2016-04-05
HK1210772A1 (en) 2016-05-06
US20160185801A1 (en) 2016-06-30
CL2015000121A1 (es) 2015-06-12
PT3312169T (pt) 2021-11-12
EP2875011A1 (en) 2015-05-27
EA025986B1 (ru) 2017-02-28
ME03005B (me) 2018-10-20
US20180072758A1 (en) 2018-03-15
AU2013290375B2 (en) 2017-11-30
EP2875011B1 (en) 2018-01-10
ES2659758T3 (es) 2018-03-19
US20150291624A1 (en) 2015-10-15
EA201590228A1 (ru) 2015-05-29
CN106478662A (zh) 2017-03-08
KR20150036692A (ko) 2015-04-07
PL2875011T3 (pl) 2018-07-31
ES2897881T3 (es) 2022-03-03
JP5778877B1 (ja) 2015-09-16
US20150182533A1 (en) 2015-07-02
DOP2015000009A (es) 2015-03-15
JP6262729B2 (ja) 2018-01-17
US9012447B2 (en) 2015-04-21
EP2875012A1 (en) 2015-05-27
JP6275675B2 (ja) 2018-02-07
DK2875011T3 (en) 2018-04-16
BR112015001028B1 (pt) 2022-12-06
HK1252279A1 (en) 2019-05-24
SI2875011T1 (en) 2018-06-29
JP2015522618A (ja) 2015-08-06
BR112015001028A2 (pt) 2017-06-27
US9670229B2 (en) 2017-06-06
US10125145B2 (en) 2018-11-13
SG11201500302UA (en) 2015-04-29
CN104768943A (zh) 2015-07-08
JP2015522619A (ja) 2015-08-06
US10407443B2 (en) 2019-09-10
UY34912A (es) 2014-02-28
WO2014014962A1 (en) 2014-01-23
PE20150671A1 (es) 2015-05-06
IL236702A0 (en) 2015-02-26
PL3312169T3 (pl) 2022-01-24
HRP20180523T1 (hr) 2018-06-01
CN106478662B (zh) 2019-07-02
GEP201606526B (en) 2016-08-10
JP2016040278A (ja) 2016-03-24
JP2015166357A (ja) 2015-09-24
TWI602821B (zh) 2017-10-21
CY1120881T1 (el) 2019-12-11
CR20150057A (es) 2015-03-26
AP2015008240A0 (en) 2015-01-31
PH12015500085A1 (en) 2015-04-13
CN104768943B (zh) 2016-11-16
MX359733B (es) 2018-10-09
US9695195B2 (en) 2017-07-04
IL236702B (en) 2018-12-31
MX2015000783A (es) 2015-05-07
DK3312169T3 (da) 2021-12-13
MY182432A (en) 2021-01-25
US20160251373A1 (en) 2016-09-01
ZA201500781B (en) 2016-04-28
TW201422626A (zh) 2014-06-16

Similar Documents

Publication Publication Date Title
JOP20130213B1 (ar) معارضات لمستقبلht3-5
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
UA113051C2 (xx) Гетероциклічні похідні та їх застосування у лікуванні неврологічних розладів
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
MX363127B (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
MX379110B (es) Derivados de azaspiro como antagonistas de trpm8.
MD20150091A2 (ro) Compuşi antivirali
MY177031A (en) Tetrahydropyridopyrazines modulators of gpr6
EA201490888A1 (ru) Новые производные пурина и их применение для лечения заболевания
MX2013008431A (es) Antagonista del receptor de mineralocorticoides.
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
MX2016007128A (es) Compuestos del receptor 6 de quimiocina (ccr6).
MD4583B1 (ro) Piridinone biciclice noi
EA201790519A1 (ru) Терапевтические соединения в качестве ингибиторов рецептора орексина-1
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
MX2015011536A (es) Nuevos antagonistas de receptores trpa1 de sulfamidas.
MX369025B (es) Inhibidores de aldosterona sintasa.
UA117154C2 (uk) Антагоністи s1p3
MY176521A (en) Pyrrole-substituted indolone derivative, preparation method therefor, composition comprising the same and use thereof
PH12016501393A1 (en) Substituted bicyclic heteroaryl compounds as rxr agonists
WO2014014794A3 (en) Mineralocorticoid receptor antagonists
NZ702239A (en) Heteroaryl compounds and methods of use thereof
MX2014003455A (es) Derivados de metanosulfonamida sustituidos con arilo o n-heteroarilo como ligandos de receptor vanilloide.